氨磷汀治疗特发性血小板减少性紫癜高龄患者近期疗效观察

为了研究氨磷汀治疗特发性血小板减少性紫癜（ITP）的近期疗效，对3例用氨磷汀治疗的特发性血小板减少性紫瘕的高龄患者进行了观察。患者的年龄分别为88、75和65岁。治疗方案为氨磷汀400毫克／天，每周连续5天静脉滴注后，休息2天，连用4周。结果表明：治疗4周以后3例患者均出现很好的近期疗效，2例患者血小板数在治疗开始后第1周恢复正常，1例在治疗2周后恢复正常，所有患者在治疗停止4个月后血小板数仍保持在正常水平．不需要激素、丙种球蛋白等其他治疗措施，且未见明显的毒副作用。结论：氨磷汀治疗高龄ITP患者具有良好的近期疗效，提示氨磷汀在ITP治疗方面有着良好的应用前景，但对其长期临床疗效有待进一步研究。

Early Effect of Amifostine in Treating Aged Patients with Idiopathic Thrombocytopenia Purpura

The purpose of this study was to explore the effect of amifostine in treating aged patients with idiopathic thrombocytopenic purpura (ITP). Three aged ITP patients (one aged 88, one aged 75, another aged 65) were treated with amifostine over a period of 4 weeks for each. The results showed that the early positive responses were observed in all 3 aged patients after treatment with amifostine 5 x 400 mg per week for 4 weeks, the recovery of platelet counts to normal level were found in 2 cases after 1 week and in 1 case after 2 weeks. Following 4 months after stop of treatment with amifostine, the normal platelet counts still remains in all patients, no more blood transfusions, hormonal preparation and gamma-globulin were given. Amifostine has never been reported elewhere as to treat of aged ITP. In conclusion, amifostine has a good early therapeutic effect on aged ITP patients, but its clinical outcome of long-term still needs further evaluation.